Article
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
Molecular cancer - 28 Sept 2024
Yang Ke, Fu Kai, Zhang Hong, Wang Xiaokun, To Kenneth K W, Yang Caibo, Wang Fang, Chen Zhe-Sheng, Fu Liwu
Abstract excerpt
BACKGROUND: BCR-ABL is a constitutively active tyrosine kinase that stimulates multiple downstream signaling pathways to promote the survival and proliferation of chronic myeloid leukemia (CML) cells. The clinical application of specific BCR-ABL tyrosine kinase inhibitors (TKIs) has led to significantly improved prognosis and overall survival in CML patients compared to previous treatment regimens. However,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.